Table 4.
Adjusted hazard ratio for all-cause mortality, cardiovascular mortality, and heart failure hospitalization based on decline in estimated glomerular filtration rate at 2- and 6-weeks, limited to the enalapril arm
| eGFR Decline | Reference (% Decline with Enalapril) | All-Cause Mortality HR (95% CI) | Cardiovascular Mortality HR (95% CI) | Heart Failure Hospitalization HR (95%) |
|---|---|---|---|---|
| At 2 weeks | ||||
| 5% | 0% | 1.06 (0.99, 1.12) | 1.06 (0.99, 1.13) | 1.02 (0.95, 1.10) |
| 10% | 0% | 1.11 (0.99, 1.24) | 1.12 (0.99, 1.27) | 1.05 (0.92, 1.21) |
| 15% | 0% | 1.15 (1.00, 1.32) | 1.17 (1.01, 1.35) | 1.09 (0.93, 1.29) |
| 20% | 0% | 1.18 (1.02, 1.36) | 1.20 (1.03, 1.40) | 1.14 (0.96, 1.36) |
| 25% | 0% | 1.20 (1.02, 1.41) | 1.23 (1.04, 1.46) | 1.20 (1.00, 1.45) |
| 30% | 0% | 1.21 (0.99, 1.48) | 1.26 (1.02, 1.55) | 1.27 (1.01, 1.58) |
| 35% | 0% | 1.23 (0.96, 1.57) | 1.29 (0.99, 1.67) | 1.33 (1.01, 1.75) |
| 40% | 0% | 1.24 (0.92, 1.68) | 1.31 (0.96, 1.80) | 1.40 (1.01, 1.94) |
| At 6 weeks | ||||
| 5% | 0% | 1.04 (0.98, 1.11) | 1.05 (0.98, 1.12) | 0.99 (0.92, 1.06) |
| 10% | 0% | 1.08 (0.96, 1.21) | 1.09 (0.96, 1.24) | 0.98 (0.85, 1.12) |
| 15% | 0% | 1.11 (0.96, 1.28) | 1.12 (0.96, 1.31) | 0.99 (0.83, 1.18) |
| 20% | 0% | 1.12 (0.96, 1.31) | 1.14 (0.96, 1.34) | 1.03 (0.85, 1.24) |
| 25% | 0% | 1.13 (0.96, 1.33) | 1.15 (0.96, 1.37) | 1.08 (0.89, 1.31) |
| 30% | 0% | 1.13 (0.94, 1.36) | 1.15 (0.95, 1.41) | 1.15 (0.93, 1.42) |
| 35% | 0% | 1.13 (0.90, 1.41) | 1.16 (0.91, 1.46) | 1.23 (0.96, 1.57) |
| 40% | 0% | 1.13 (0.86, 1.48) | 1.16 (0.88, 1.54) | 1.31 (0.98, 1.75) |
Analysis performed using Cox proportional hazard regression models with 0% decline on enalapril as the reference. Models adjusted for age, sex, race, previous myocardial infarction, smoking, NYHA functional class, diastolic blood pressure, baseline eGFR, potassium, hematocrit, and trial (Prevention or Treatment).